Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: Results from a phase II Trial (SAKK 08/07)

Clinical Cancer Research

Volumn 18, Issue 21, 2012, Pages 6049-6057

  Cathomas, Richard ^a   Rothermundt, Christian ^b   Klingbiel, Dirk ^c   Bubendorf, Lukas ^e   Jaggi, Rolf ^d   Betticher, Daniel C ^g   Brauchli, Peter ^c   Cotting, Denise ^c   Droege, Cornelia ^f   Winterhalder, Ralph ^b   Siciliano, Daniele ^h   Berthold, Dominik R ^j   Pless, Miklos ^k   Schiess, Ralph ⁱ   Von Moos, Roger ^a   Gillessen, Silke ^b  

^a Medical Oncology   (Switzerland)

^b Kantonsspital St Gallen ^*  (Switzerland)

^c SAKK Coordinating Centre   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g Hopital Cantonal de Fribourg   (Switzerland)

^h Stadtspital Triemli   (Switzerland)

ⁱ ETH ZURICH   (Switzerland)

^j REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^k CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; RNA;

ACNE; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ANOREXIA; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DYSPNEA; EGFR GENE; ENZYME ACTIVITY; ERYSIPELAS; FATIGUE; FEBRILE NEUTROPENIA; FOLLICULITIS; GENE; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; IMMUNOHISTOCHEMISTRY; INTESTINE FISTULA; INTESTINE PERFORATION; LEUKOPENIA; LUNG INFECTION; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEWBORN EXFOLIATIVE DERMATITIS; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PRURITUS; PTEN GENE; RECTUM HEMORRHAGE; SEPSIS; SEPTICEMIA; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84868530207     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2219     Document Type: Article

References (39)

1. Tannock IF, de Wit R, Berry DR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. (Pubitemid 39315317)
2. Festuccia C, Angelucci A, Gravinia GL, Biordi L, Millimaggi D, Muzi P, et al. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 2005;93:964-75. (Pubitemid 40691556)
3. Di Lorenzo G, Tortora G, Di'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44. (Pubitemid 35340719)
4. Ross JS, Gray KE, Webb IJ, Gray GS, Rolfe M, Schenkein DP, et al. Antibody-based therapeutics: focus on prostate cancer. Cancer Metastasis Rev 2005;24:521-37. (Pubitemid 43096999)
5. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-37. (Pubitemid 47325606)
6. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27:2622-29.
7. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42.
8. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Antiepidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996;56:3666-69. (Pubitemid 26272010)
9. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996;19:419-27.
10. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002;8:1253-64. (Pubitemid 34517666)
11. Scher HI, Halabi S, Tannock I, Morris N, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008;26:1148-59.
12. Ruiz C, Oeggerli M, Schneider S, Gonzales IM, Kiefer JM, Zellweger T, et al. Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer. J Pathol 2011;223:543-52.
13. Oberli A, Popovici V, Delorenzi M, Baltzer A, Antonov J, Matthey S, et al. Expression profiling with RNA from formalin-fixed, paraffin-embedded material. BMC Medical Genomics 2008;1:9.
14. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
15. Herndon JE. A design alternative for two-stage, phase II, multicenter cancer clinical trials. Control Clin Trials 1998;19:440-50.
16. RCore Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. ISBN 3-900051-07-0. Available from: http://www.R-project.org/.
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005;2:416-22. (Pubitemid 43115010)
18. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010;46:1770-72.
19. Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009;20:703-8.
20. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008;112:521-6. (Pubitemid 351186193)
21. Canil CM, Moore MJ, Winquist E, Baetz T, Pollack M, Chi KN, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23:455-60. (Pubitemid 46224221)
22. Gravis G, Bladou F, Salem N, Goncalves A, Esterni B, Walz J, et al. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 2008;19:1624-28.
23. Nabhan C, Lestingi TM, Galvez A, Tolzien K, Kelby SK, Tsarwhas D, et al. Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial. Urology 2009;74:665-71.
24. Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, et al. Dose and schedule of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008;14:502-8. (Pubitemid 351226119)
25. Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P, Mendelsohn J, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus doxorubicin in the treatment of metastatic castration resistant prostate cancer. Clin Genitourin Cancer 2009;7:E77-82.
26. Fleming MT, Sonpavde G, Kolodziej M, Awashti S, Hutson TE, Martincic D, et al. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2012;10:6-14.
27. Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 2006;119:1858-62. (Pubitemid 44356843)
28. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer? Brit J Cancer 2008;99:1296-301.
29. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, et al. PTEN genomic deletion is associated with p-Akt and AR signaling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009;218:505-13.
30. Uzoh CC, Perks CM, Bahl A, Holly JM, Sugiono M, Persad RA. PTEN-mediated pathways and their association with treatment-resistant prostate cancer. BJU Int 2009;104:556-61.
31. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005;8:108-18. (Pubitemid 43118073)
32. Bouali S, Chrétien AS, Ramacci C, Royer M, Becuwe P, Merlin JL. PTEN expression controls cellular response to cetuximab bymediating PI3K/AKT and RAS/RAF/MAPK downstream signalling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep 2009;21:731-35.
33. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011;3:72ra17.
34. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
35. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. Epub 2012 Aug 15.
36. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
37. Kantoff PW, Higano CS, Shore ND, Berger R, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
38. Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer patients with bone metastases (ALSYMPCA). J Clin Oncol 30, 2012 (suppl; abstr LBA4512).
39. Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, et al. Epidermal growth factor receptor EGFR) analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer 2011;11:31.